Tislelizumab and Zeprumetostat Show Promise in NK/T-Cell Lymphoma Phase Ib/II Trial
A phase Ib/II trial is evaluating the combination of tislelizumab and zeprumetostat in relapsed or refractory NK/T-cell lymphoma, focusing on determining the recommended phase II dose and assessing efficacy.